CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,140 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05244668
NCT05244668N/ACompleted

Multicenter Validation of the Salivary miRNA Signature of Endometriosis - The ENDOmiARN Salive Test Study

ZIWIG·observational·Posted Feb 17, 2022·Updated Mar 27, 2026

In Brief

An observational study for Endometriosis. Completed, enrolled 1,140 participants across 18 sites in 2 countries.

Detailed Summary

ENDOmiARN Salive Test is a multicentre external validation study of a salivary signature of endometriosis carried out in France in Obstetrics and Reproductive Medicine departments, in order to evaluate its performance and discuss its use in clinical practice. The clinical application is to significantly reduce the time to diagnosis and improve the care pathway for endometriosis. The study population is made up of women aged 18 to 43 years with formally diagnosed endometriosis or suspected endometriosis who are already receiving either medical (MAP) or surgical treatment as part of their routine care. The patients concerned by the study are managed without any change in the care pathway, nor any change in the therapeutic indications, nor any change in the diagnostic examinations (imaging or biology) required according to the context, which are carried out in accordance with the HAS recommendations. In this study, the management and follow-up of patients : * Are not imposed by the study: the doctor remains free to make medical prescriptions (treatments and examinations) and to determine the interval between consultation visits, * Are not modified in comparison with the usual follow-up, except for the performance of : * Collection of saliva * Electronic collection of the answers to the questionnaires completed by the patient

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis
CountriesCanada, France

Timeline

N/ACompletedFinished
20222023202420252026
First PostedFeb 17, 2022
Enrollment StartDec 15, 2021
Primary CompletionJan 6, 2023
Study CompletionFeb 28, 2026
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.4 years ago